The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
R | Respiratory system | |
2
|
R03 | Drugs for obstructive airway diseases | |
3
|
R03D | Other systemic drugs for obstructive airway diseases | |
4
|
R03DX | Other systemic drugs for obstructive airway diseases | |
5
|
R03DX12 |
| Active Ingredient |
|---|
|
Depemokimab targets human IL-5 with a binding affinity of 10.5 pM, thereby blocking the binding to the IL-5 receptor alpha expressed on the cell surface with picomolar potency (IC50 4 pM) in vitro. IL-5 is a pleiotropic cytokine with established impact on eosinophils and other immune and structural cells. In severe asthma, inhibition of IL-5 has demonstrated an improvement in epithelial integrity, mucus plugging and reduction in tissue remodelling. However, the mechanism of action has not been definitively established. |
| Document | Type | Information Source | |
|---|---|---|---|
| EXDENSUR Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| EXDENSUR Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.